Non-Hodgkin’s Lymphoma

Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy (07-25-2017)

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell Acute Lymphoblastic Leukemia.  CAR-T also shows promise in ALL, CLL, other B-cell malignancies, and other... Continue Reading

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (07-12-2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma (05-4-2017)

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76%... Continue Reading

Imbruvica® is approved by FDA for Marginal Zone Lymphoma (02-7-2017)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. These data were... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (01-5-2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan® (rituximab) plus chemotherapy, and should now be... Continue Reading

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma (12-15-2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (12-1-2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (08-16-2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (06-20-2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma (06-8-2016)

Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab)... Continue Reading

« Previous PageNext Page »